AI Eye Screening System
As your eyes are the windows to the world, AI-based solutions are being designed, developed, and trained to diagnose retinal-associated diseases and disorders to treat the populace at an affordable cost yet with accurate results. Thus, OPHTHA AES is capable of detecting conditions (automatically segmenting pathological features) related to DR and detecting the existence of DR and pathological features (exudates, hemorrhages, microaneurysms, neovascularization) based on which the classification is done.
We're revolutionizing diabetic retinopathy detection through AI-powered technology, making diagnosis faster, more accurate, and accessible to everyone.
Utilizing state-of-the-art artificial intelligence for accurate retinopathy detection.
Developed in collaboration with leading ophthalmologists and medical professionals.
Focused on providing accessible and affordable diagnostic solutions for all patients.
To realize a day where each and everyone on the planet can afford and access modern technological products to lead a healthier life.
To innovate AI-driven predictive and preventive solutions with the right fusion of advanced diagnostics to save and improve more human lives.
From retinal image screening to grading for DR standards to reporting and flagging, our system operates as a fully autonomous solution.
Our solution offers you with high results performance figures including 87.7% validation accuracy and 81.1% test accuracy.
Your data is secured and confidential with us. Ophtha AES uses novel and effective encryption and decryption technologies end-to-end, with highest level of compliance.
Setting new standards in AI-powered medical diagnostics with proven results and recognition.
Ophtha AES was awarded as the first runners up in "Sirasa Kotiyak Watina Adahasak" competition in 2018.
Leading research and innovation in AI-powered medical diagnostics.
Hemorrhages are one of the earliest signs of Diabetic Retinopathy, hence accurate detection of hemorrhages is crucial in an automated DR detection system. In this paper, a novel and robust rule based methodology for automated detection of hemorrhages is proposed.
Read More
Neovascularization is one of the retinal signs we see in the proliferative stage of diabetic retinopathy (DR). This paper highlights a novel and a robust methodology for neovascularization detection.
Read MoreExplore our comprehensive learning resources and educational materials.
Meet the experts behind Ophtha AES
MBBS
Chief Executive Officer
BSc. Eng, MSc. Eng
Chief Technology Officer
MBBS
Head of clinical studies
BSc. Eng, MSc. Business intelligence
Software Engineer
MBBS
Researcher
Get in touch with us to discuss your project requirements
Bay X, Trace Expert City, Maradana Road
Colombo 10, Sri Lanka.
076 621 0120
dhanuh.es@gmail.com